HCRx Bets Big on Brain Cancer Drug Modeyso in New Royalty Deal

STAMFORD, Conn. – April 22, 2026 – In a move that underscores the immense value placed on breakthrough cancer therapies, HealthCare Royalty (“HCRx”) has acquired a portion of the future royalties for Modeyso® (dordaviprone), a recently approved drug offering the first glimmer of hope for patients with a rare and aggressive form of brain cancer.

The Stamford-based investment firm announced it has entered into a royalty monetization agreement with the advisory group representing the former securityholders of Oncoceutics Inc., the original developer of the drug. While the financial terms and the exact percentage of royalties acquired remain undisclosed, the deal signals strong confidence in the commercial trajectory of Modeyso, which is being commercialized by pharmaceutical giant Jazz Pharmaceuticals.

This transaction highlights a sophisticated financial ecosystem that works behind the scenes of medical innovation, providing crucial liquidity to early-stage developers and allowing investment firms to share in the success of life-saving treatments.

A Landmark Therapy for a Devastating Disease

At the heart of this financial agreement is a medical breakthrough: Modeyso. Approved by the U.S. Food and Drug Administration under its accelerated approval pathway in August 2025, the drug is a targeted therapy for adult and pediatric patients with H3 K27M-mutant diffuse midline glioma (DMG). This specific type of brain tumor is one of the most challenging diagnoses in oncology.

DMGs are highly aggressive tumors that arise in the midline structures of the brain, such as the brainstem and thalamus. Their diffuse nature, infiltrating healthy brain tissue like roots in soil, makes them notoriously difficult, and often impossible, to remove surgically. The presence of the H3 K27M mutation, a specific genetic alteration, is a hallmark of the disease and is associated with a particularly grim prognosis. Primarily affecting children and young adults, the median survival time has historically been less than a year from diagnosis.

Before Modeyso, patients and their families faced a landscape devoid of effective options. Standard-of-care radiation therapy could provide temporary relief but did not meaningfully alter the disease's relentless course, and conventional chemotherapies have proven largely ineffective. Modeyso’s approval marked a pivotal moment, representing the first-ever therapy specifically approved for this patient population and directly addressing what HCRx Chairman and CEO Clarke Futch called a “significant unmet need.”

The Financial Engine: Monetizing Future Success

HealthCare Royalty's investment is a classic example of royalty monetization, a common yet complex financial strategy in the biopharmaceutical industry. In essence, the former securityholders of Oncoceutics have sold the rights to a portion of their future income stream from Modeyso sales to HCRx in exchange for a significant upfront payment.

For the sellers, this transaction provides immediate liquidity, converting a long-term, uncertain revenue stream into present-day capital. It allows these early investors and founders to de-risk their position and realize a return on their foundational work without waiting years for royalty checks to trickle in. For a buyer like HCRx, the deal offers a chance to invest in a de-risked, FDA-approved asset with strong market potential.

The confidence behind the deal is bolstered by the drug’s initial reception. “Since its launch in August, Modeyso has demonstrated strong early performance, reflecting the significant unmet need, high awareness driven by advocacy groups, and the value physicians see for patients with H3 K27M-mutant diffuse midline glioma,” Futch stated in the announcement. This strong uptake suggests a promising revenue curve, making the future royalty stream a valuable asset worth acquiring.

From Lab Bench to Market: The Journey of Modeyso

The path of Modeyso from a laboratory concept to a commercial product is a case study in the modern biopharma ecosystem, which relies on a relay of different specialists. The journey began at Oncoceutics Inc., a biotech firm that discovered the molecule, then known as ONC201.

Oncoceutics successfully navigated the drug through its critical early stages, from initial discovery and preclinical studies to demonstrating its potential in Phase II clinical trials. This phase is often where smaller, innovation-focused biotechs excel. However, the final, most expensive stages of development—large-scale Phase III trials, navigating the complex FDA approval process, and building a global commercial infrastructure—often require the resources of a much larger organization.

At some point after the promising Phase II data emerged, the asset was transferred to Jazz Pharmaceuticals, a global biopharmaceutical company with the scale and experience to bring Modeyso to market. As part of that original acquisition or licensing deal, the founders and investors of Oncoceutics retained rights to a percentage of the drug's future sales—the very royalties that are now the subject of the HCRx agreement.

This long-term vision was affirmed by Lee Schalop, co-founder and former CEO of Oncoceutics. “On behalf of all of the former shareholders of Oncoceutics, we are pleased that HCRx shares our belief that Modeyso can create significant value as a new treatment option for patients,” he said, acknowledging the new chapter in the drug's financial lifecycle.

HCRx's Strategic Play in Biopharma Finance

This deal is not an isolated bet but a calculated move that fits squarely within HealthCare Royalty’s established investment strategy. Founded in 2006 and majority-owned by the global investment powerhouse KKR & Co. Inc., HCRx has carved out a niche as a leading provider of innovative capital to the life sciences industry. With over $7 billion committed across more than 110 products, the firm specializes in identifying and investing in late-stage and commercial-stage assets.

HCRx’s model focuses on providing non-dilutive capital, meaning it offers funding without forcing companies to issue new stock and dilute the ownership of existing shareholders. The Modeyso deal is a prime example of its thesis in action: investing in an approved, revenue-generating product that addresses a critical unmet need and is marketed by a top-tier pharmaceutical partner. The backing from KKR provides HCRx with substantial financial firepower and strategic reach, enabling it to execute sophisticated transactions in a competitive landscape.

By acquiring a piece of Modeyso's future, HCRx is not only expanding its portfolio with a high-potential oncology asset but also reinforcing the financial pathways that incentivize innovation. This flow of capital, from large investors back to the original innovators, is a critical component of the high-risk, high-reward world of drug development, ensuring that the search for the next breakthrough therapy remains a viable and attractive endeavor.